Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation.
Maartje S JacobsLisa A de JongMaarten J PostmaRobert G TielemanMarinus van HulstPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2017)
The use of rivaroxaban in elective ECV is a cost-effective alternative to the use of VKAs. Rivaroxaban has a 50% probability of being cost-saving compared with VKAs and would increase a patient's quality of life when non-health care costs such as productivity loss and informal care costs are taken into account.
Keyphrases
- atrial fibrillation
- healthcare
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- patients undergoing
- venous thromboembolism
- heart failure
- percutaneous coronary intervention
- public health
- pulmonary embolism
- palliative care
- mental health
- case report
- health information
- affordable care act
- pain management
- coronary artery disease
- left ventricular